Use of asthma medication in COVID-19 patients with underlying asthma
| Parameters | N (%) in the last one year | N (%) in the last two months |
| ICS alone | 66 (30.3%) | 58 (26.6%) |
| ICS-LABA | 84 (38.5%) | 78 (35.8%) |
| Inhaled LABA | 0 (0.0%) | 0 (0.0%) |
| Oral LABA | 77 (35.3%) | 70 (32.1%) |
| Patch LABA | 41 (18.8%) | 36 (16.5%) |
| LTRA | 160 (73.4%) | 145 (66.5%) |
| Inhaled SABA | 83 (38.1%) | 75 (34.4%) |
| Oral SABA | 30 (13.8%) | 8 (3.7%) |
| Xanthine | 110 (50.5%) | 100 (45.9%) |
| Inhaled LAMA | 25 (11.5%) | 25 (11.5%) |
ICS: inhaled corticosteroids; LABA: long-acting β2-agonists; LAMA: long-acting muscarine antagonists; LTRA: leukotriene receptor antagonists; SABA: short-acting β2-agonists.